Glaxosmithkline Pharmaceuticals Ltd
Glaxosmithkline Pharmaceuticals Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #64 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
The company aims to achieve double-digit top-line growth, maintaining strong momentum with new product launches and innovation. The company aims for double-digit top-line growth, despite recent muted growth (2% in FY26, 8% in FY25, 7% in FY24); the ambition remains undiluted.
From Glaxosmithkline Pharmaceuticals Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company aims to achieve double-digit top-line growth, maintaining strong momentum with new product launches and innovation.
- Volumes have been growing at least in double-digits for the last two successive financial years for assets included in NLEM.
- GenMed business is expected to rebound to consistent 6-8% top-line growth after overcoming supply constraints.
- Vaccines portfolio is projected to grow in high double digits, driven by adult vaccines such as Shingrix and continued momentum in pediatric vaccines.
- Specialty portfolio, including oncology and new respiratory products, is scaling up with a focus on innovative, high-growth areas.
- 26 ongoing clinical trials in unmet medical needs signal pipeline-driven future growth.
2 more points from Glaxosmithkline Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Glaxosmithkline Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Significant launches planned in the next six months for the locally listed entity, including two in oncology and one adult vaccine, indicating ongoing investment in growth.
- Continuous investment focus on growing the business, with a preference to reinvest rather than prioritize EBITDA margin expansion.
- Emphasis on building innovative and specialty-led business segments (oncology, vaccines, respiratory), implying capital allocation towards these high-growth areas.
- Active work on cost optimization and digital initiatives (AI and IA) to enhance productivity and efficiency.
- Robust business continuity planning and alternative contingencies have been put in place to avoid supply issues, suggesting investments in supply chain resilience.
2 more points from Glaxosmithkline Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Glaxosmithkline Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Glaxosmithkline Pharmaceuticals Ltd said on order book & pipeline — free account, 30 seconds.
Glaxosmithkline Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹995 Cr, net profit ₹278 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Glaxosmi. Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharma (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pha. (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Guj. Themis Bio. (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Glaxosmithkline Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Glaxosmithkline Pharmaceuticals Ltd Q4 FY26 results?
The company aims to achieve double-digit top-line growth, maintaining strong momentum with new product launches and innovation. The company aims for double-digit top-line growth, despite recent muted growth (2% in FY26, 8% in FY25, 7% in FY24); the ambition remains undiluted.
What is Glaxosmithkline Pharmaceuticals Ltd share price analysis?
Glaxosmithkline Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 43.3 with a market cap of ₹45,550 Cr. Investors should review the full earnings analysis for detailed insights.
Is Glaxosmithkline Pharmaceuticals Ltd planning capital expenditure?
Significant launches planned in the next six months for the locally listed entity, including two in oncology and one adult vaccine, indicating ongoing investment in growth.
Keep Glaxosmithkline Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.